Moral majority take on GSK and Merck over cancer drugs
Sunday 11 June 2006
Pharmaceutical giants Merck and GlaxoSmithKline are gearing up for a bruising showdown with America's religious right after the US medicines regulator approved a new blockbuster cervical cancer vaccine last week.
Conservative groups, including the influential Family Research Council (FRC), have voiced concerns that immunising young girls against the virus that most regularly causes cervical cancer, Human Papilloma- virus, may lead to sexual promiscuity. "We would oppose any measures to legally require vaccination or to coerce parents into authorising it," wrote the FRC in a recent letter to the US government. "Our primary concern is with the message that would be delivered to nine- to 12-year-olds with the administration of the vaccines. Care must be taken not to communicate that such an intervention makes all sex 'safe'."
The Food and Drug Administration's approval of Gardasil, Merck's vaccine, is likely to increase the volume of such complaints ahead of a meeting on 29 June of the Advisory Committee on Immunization Practices. The ACIP is the body that will recommend how, and if, Gardasil should be integrated in the schedule of other mandatory vaccines, such as against polio.
Glaxo filed for registration of its Cervarix vaccine in Europe in March, and expects to file in the US before the year is out. Merck expects approval in Europe later this summer.
Merck and Glaxo have been in discussions with Christian conservative groups in America to assuage their concerns. Lobbying organisations such as the FRC exercise considerable political power, and if they succeed in pushing their agenda it "certainly could have a negative impact" on the use of the vaccine, said Mike Ward, an analyst at Nomura Code Securities.
ACIP's decision will be crucial to the overall penetration of the vaccine in the US, the world's largest drug market. Merck plans to charge $360 (around £200) for the three-jab course given over six months. It estimates that in the US alone there are 32 million females between the ages of nine and 24 - the range for which the FDA approved the vaccine. This equates to $11.5bn.
Ideally, the vaccine should be given at an early age because the Human Papillomavirus it targets is the primary cause of cervical cancer and is passed through sexual contact.
The vaccine does not eliminate the virus in women who are already infected. "For a prophylactic vaccine, it should [be given] before the risk occurs," said Philipe Monteyne, head of Glaxo's vaccines unit.
- 1 James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
- 2 ALS ice bucket challenge co-founder Corey Griffin drowns aged 27
- 3 Cilla Black defends Cliff Richard: 'I am positive that the allegations are without foundation'
- 4 Nicki Minaj finally releases predictable 'Anaconda' video
- 5 James Foley 'beheading': Met police warn public watching murder video could be criminal offence
James Foley 'beheaded': PM cuts holiday short for emergency meeting on British response to latest Isis atrocity
Michael Brown shooting: Police shoot and kill second young black man near Ferguson
ALS ice bucket challenge co-founder Corey Griffin drowns aged 27
James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
Iraq crisis: Islamic State's message to America - 'We will drown you all in blood'
Scottish independence: English people overwhelmingly want Scotland to stay in the UK
Isis threat: Cameron wants an alliance with Iran
Crisis? What crisis? A visiting US doctor gives the NHS a rave review
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
Richard Dawkins on babies with Down Syndrome: 'Abort it and try again. It would be immoral to bring it into the world'
Scottish Independence Referendum: Salmond described as 'arrogant, ambitious and dishonest' by Scottish women
iJobs Money & Business
£45000 per annum: Harrington Starr: Quantitative Analyst (Financial Services, ...
Negotiable: Harrington Starr: Application Support Engineer (C++, .NET, VB, Per...
£450 - £600 per day: Harrington Starr: AIFMD Business Analyst / Consultant - I...
£450 - £600 per day: Harrington Starr: Business Analyst Solvency II SME (Pilla...